

# 東邦大学学術リポジトリ

Toho University Academic Repository

タイトル	A preliminary study of the potential role of FGF 23 in coronary calcification in patients with suspected coronary artery disease
別タイトル	冠動脈疾患が疑われた患者における冠動脈石灰化とFGF 23の関係
作成者(著者)	正井, 博文
公開者	東邦大学
発行日	2013.11
掲載情報	東邦大学大学院医学研究科 博士論文. 17.
資料種別	学位論文
内容記述	主査: 池田隆徳 / タイトル: A preliminary study of the potential role of FGF 23 in coronary calcification in patients with suspected coronary artery disease / 著者: Hirofumi Masai, Nobuhiko Joki, Kaoru Sugi, Masao Moroi / 掲載誌: Atherosclerosis / 巻号・発行年等: 226(1):228-233, 2013 / 本文ファイル: 査読後原稿
著者版フラグ	ETD
報告番号	32661乙第2803号
学位授与年月日	2013.11.28
学位授与機関	東邦大学
DOI	info:doi/10.1016/j.atherosclerosis.2012.10.045
メタデータのURL	<a href="https://mylibrary.toho-u.ac.jp/webopac/TD76949806">https://mylibrary.toho-u.ac.jp/webopac/TD76949806</a>

Title:

A preliminary study of the potential role of FGF23 in coronary calcification in patients with suspected coronary artery disease

Hirofumi Masai<sup>1</sup>, MD

Nobuhiko Joki<sup>2</sup>, MD, PhD

Kaoru Sugi<sup>1</sup>, MD, PhD

Masao Moroi<sup>3</sup>, MD, PhD

<sup>1</sup> Division of Cardiovascular Medicine, and <sup>2</sup> Division of Nephrology, TOHO University Ohashi Medical Center

<sup>3</sup> Cardiology Division, National Center for Global Health and Medicine

Address for correspondence:

Nobuhiko Joki, MD, PhD, Associate Professor

Division of Nephrology, TOHO University Ohashi Medical Center, 2-17-6, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan

Phone: +81-3-3468-1251; Fax: +81-3-3468-1269;

E mail: jokinobuhiko@gmail.com

Short title: Fibroblast growth factor 23 and coronary calcification

Word count: 2787, Tables: 5, Figures: 2

## **Abstract**

**Objective:** The association of fibroblast growth factor 23 (FGF-23) with vascular disease in patients with preserved renal function is not well understood. The purpose of this study was to investigate the relationship of serum FGF-23 with coronary calcification in patients without chronic kidney disease and diabetes mellitus (DM).

**Methods:** A cross-sectional study was performed in 148 consecutive patients with suspected coronary artery disease who underwent 64-slice computed tomography coronary angiography for diagnosis of coronary artery disease. Patients with eGFR <60 mL/min/1.73m<sup>2</sup>, proteinuria, or DM were excluded. Associations of coronary calcification (evaluated by Agatston score) were examined with classical risk factors and with inflammatory markers, adipocytokines and FGF-23.

**Results:** The median creatinine, eGFR and FGF-23 levels were 0.7 mg/dL, 74.6 mL/min/1.73m<sup>2</sup>, and 26 pg/mL respectively. The strongest association was found between age and Agatston score ( $r=0.367$ ,  $p<0.001$ ) in univariate logistic regression analysis. No atherogenic risk factors, including inflammatory markers and adipocytokine levels, were associated with Agatston score. Among calcium/phosphate metabolism markers, FGF-23 showed a weak but significant correlation with Agatston score ( $r=0.169$ ,  $p=0.039$ ). In multivariate linear regression analysis, age and FGF-23 ( $r=0.188$ ,  $p=0.016$ ) were independently associated with the Agatston score.

**Conclusion:** Serum FGF-23 levels were associated with coronary calcification independently of classical risk factors and of adipocytokines and inflammatory markers in patients with preserved renal function. FGF-23 may also have a direct effect on progression of coronary calcification and further studies are required to examine this issue.

Key words: fibroblast growth factor 23, chronic kidney disease, arteriosclerosis, coronary artery calcification, computed tomography coronary angiography

## **1. Introduction**

Quantification of coronary artery calcification (CAC) is widely understood to be of prognostic value, since patients with no CAC have very low rates of cardiac events [1-4]. CAC is a marker of subclinical atherosclerosis that is assessed by computed tomography and is strongly associated with the risk of future coronary heart disease and mortality [5]. Thus, it is important to detect early coronary calcification to avoid future cardiac events, but there is limited information on contributors to coronary calcification that could serve as surrogate markers in the general population.

Vascular calcification is often observed in patients with chronic kidney disease (CKD), especially in the advanced stage [6]. Calcium/phosphate (Ca/phosphate) disorder, and especially higher levels of blood phosphate, secondary to renal dysfunction has a central role in vascular calcification in these patients [6]. Fibroblast growth factor 23 (FGF-23) is a bone-derived hormone that has an important function in regulating circulating phosphate and vitamin D levels [7-11]. Circulating FGF-23 levels are elevated and independently associated with mortality in patients who are starting hemodialysis treatment [12]. Interestingly, several reports have shown that a higher FGF-23 level is also associated with vascular diseases such as carotid intima-media thickness [13], calcification of the aorta [14-16] and peripheral artery [16], and severity of angiographic coronary narrowing [17] in CKD patients. It is also of interest that the FGF-23 level starts to increase in the early phase of CKD (stage 1 or 2), even when the phosphate level is in the normal range [18].

Despite these findings, the association of FGF-23 with vascular disease in a population with preserved renal function remains unclear. The purpose of this study was to explore the relationship between the serum FGF-23 level and coronary calcification in patients with preserved renal function based on an estimated

glomerular filtration rate (eGFR) over 60 mL/min/1.73m<sup>2</sup>.

## **2. Subjects and Methods**

### *2.1. Study design and patients*

We conducted a study with a cross-sectional design in 148 of 227 consecutive patients with suspected coronary heart disease who underwent computed tomography coronary angiography (CTCA) for diagnosis of coronary artery disease in our hospital from February 2010 to August 2011. The exclusion criteria were patients with eGFR <60 mL/min/1.73m<sup>2</sup>, proteinuria, and diabetes (HbA1c > 5.8% or currently taking antidiabetic drugs). These criteria led to exclusion of 79 patients. The Agatston score for CAC was determined by CTCA and the associations of this score with clinical variables and blood chemistry data including FGF-23 were examined. The study protocol was approved by the Ethics Committee for Clinical Research of Toho University Ohashi Medical Center.

### *2.2. Data collection*

Clinical information was recorded for all patients at the time of each CTCA examination. First, the patient was interviewed to obtain data on age, gender, smoking habits, previous hospitalizations, and history of hypertension, cardiac disease, cerebrovascular disease, and peripheral artery disease. Information about the use of oral medications was also collected. Blood pressure was recorded in the sitting position and a blood sample was collected just before injection of the contrast agent for CTCA. Blood samples were taken at least 4 hours after a meal. Body mass index (BMI) was calculated as weight (kg) / height<sup>2</sup> (m<sup>2</sup>). eGFR was calculated using the new Japanese equation [19]: eGFR (mL/min/1.73 m<sup>2</sup>) = 194×creatinine

$(Cr)^{-1.094} \times age^{-0.287}$  ( $\times 0.739$  for women).

### *2.3. Serum and plasma biochemistry*

All blood samples were drawn in the evening, just before CT angiograms were recorded. The subjects were instructed not to eat a meal within four hours before recording of the angiogram. Therefore, the blood samples were taken at least 4 hours after a meal. Plasma and serum samples were stored at  $-20^{\circ}\text{C}$  immediately after blood sampling. All biochemical markers were measured within 2 weeks after sampling.

Blood chemistry parameters (low- and high-density lipoprotein cholesterol, triglyceride, creatinine, albumin, calcium, and inorganic phosphate, HbA1c, immunoreactive insulin) were measured by standard automated techniques in our hospital. The biologically active form of serum FGF-23 (intact FGF-23) was measured with a sandwich ELISA system (Kainos Laboratories Inc, Tokyo, Japan) [20]. Serum  $1,25\text{-(OH)}_2\text{-D}_3$  levels were measured using a TFB  $1,25\text{-dihydroxyvitamin D}$  RIA kit (Immunodiagnostic Systems, Boldon, UK). Serum whole PTH levels were measured with a third-generation PTH assay (Scantibodies Laboratories, Santee, CA, USA). Serum levels of leptin, total adiponectin and  $\text{TNF-}\alpha$  were measured using a RIA kit (Millipore Corporation, Billerica, MA, USA), a sandwich ELISA (Otsuka Pharmaceuticals, Tokyo, Japan), and a QantiGlo ELISA Kit (QTA00B; R&D Systems Inc, Minneapolis, MN, USA), respectively. FGF-23,  $1,25\text{-(OH)}_2\text{-D}_3$ , whole-PTH, leptin, adiponectin, and  $\text{TNF-}\alpha$  levels were all determined at Mitsubishi Chemical Medience Corporation (Tokyo, Japan).

### *2.3. Urine sampling*

Of the 148 patients, 17 provided spot urine samples at the time of blood sampling.

Urine phosphate and Cr concentrations were measured by standard methods. The absolute urine phosphate concentration and this concentration adjusted by urine Cr were used for analysis. The adjusted urine phosphate concentration was calculated as urine phosphate (mg/dL) / urine Cr (mg/dL) (urine phosphate:creatinine ratio).

#### *2.4. Computed tomography coronary angiography (CTCA)*

The patients underwent 64-multislice CTCA with an Aquillion 64 system (Toshiba Medical Systems, Otawara, Japan) for diagnosis of coronary artery disease. Those with a resting heart rate >60 bpm received 1 mg/kg metoprolol orally 60 min before imaging, and all patients received 0.3 mg nitroglycerin sublingually 5 min before imaging. The settings in the 64 CTCA system were collimator 64 x 0.5 mm; detector pitch 9.8-11.2; pixel size 0.39 x 0.39 mm; gantry rotation time 350 ms; tube current 400 mA; and voltage 120 kV. Contrast agent (370 mgI/ml<sup>-1</sup>; iopamidol, Bayer Schering Pharma) was injected at a rate of 0.06 mL/kg/s for the whole scan time plus 2 s, followed by 0.15 ml/kg of contrast media and 0.15 ml/kg of saline solution with a dual injector. Acquisition of CT data and electrocardiography (ECG) were started as soon as the signal density level in the ascending aorta reached a predefined threshold of 250 HU. The effective radiation dose was 15-18 mSv. Acquisition time was reduced to 175 ms by applying a half-scan algorithm (only data from a 180° gantry rotation were used for image reconstruction) in all patients. Raw data from the scans were reconstructed using a half-scan algorithm optimized for retrograde ECG-gated reconstruction. The end of the reconstruction period was set at the peak of the P wave on the monitoring ECG [21,22]. The reconstructed CT image data were transferred to a computer workstation (Ziostation, Amin, Tokyo, Japan) for post-processing and analysis. After visual inspection of the volume-rendered images, which depicted the gross



configuration of the lumen of the coronary artery, coronary artery plaques were inspected carefully on both the axial and curved multiplanar reformatted images, and were used to classify coronary lesions visually.

### *2.5. Assessment of coronary plaques*

Images were evaluated with the optimal setting to detect plaques and outer vessel boundaries, using an average at a width representing 155% of the mean intensity within the lumen and at a level representing 65% of the mean intensity [23]. The coronary plaque area was measured by manual tracing because of the difference between the vessel area (inside area of the external elastic membrane) and the lumen area at the site of maximal lumen narrowing, as observed on cross-sectional 64-slice CTCA images. A lipid-rich plaque area was defined as an area of mean CT density <50 HU, which was automatically traced and measured on the workstation (Ziostation). An area with a mean CT density <50 HU is thought to be a lipid-rich plaque on IVUS images [24]. Agatston scores for CAC were determined using software for evaluation of calcification.

### *2.6. Statistical analysis*

Data are expressed as the median and interquartile range. Pearson univariate regression analysis was used to evaluate the association of clinical factors with Agatston scores. Dummy variables were used for gender (0 for female, 1 for male), smoking history (0 for negative, 1 for positive), and use of each medication (0 for not used, 1 for used). In all analyses,  $P < 0.05$  was considered significant. All analyses were performed using StatView for Windows v. 5.0 (SAS Institute, Cary, NC).

### 3. Results

#### 3.1. Patient characteristics

The 148 subjects had a median age of 65.5 years old (range: 27 to 84 years old), about half were male, and about half were smokers. Median BMI was 23.1, which is similar to the value found in epidemiological studies of the general population in Japan. Medical history, medications and biochemical data are shown in Table 1. The median Cr level and eGFR were 0.7 mg/dL and 74.6 mL/min/1.73m<sup>2</sup>, respectively, indicating preserved renal function. The median level of FGF-23 was 26 pg/mL, which is almost the same as that in the general Japanese population [25]. Log transformed FGF-23 is also shown in Table 1 and histograms of absolute and Log transformed FGF-23 levels are shown in Figure 1. Absolute FGF-23 had a near normal distribution. The median calcium, phosphate, whole-PTH, and 1,25-(OH)<sub>2</sub>-D<sub>3</sub> levels were 9.5 mg/dL, 3.7 mg/dL, 36.6 pg/mL, and 56 pg/mL respectively, all of which were within the normal ranges. Lipid profile, inflammation markers, and adipocytokines are also shown in Table 1. Coronary characteristics from the CT angiogram are shown in Table 2. The median Agatston score was 11.5 (range, 0 to 1445) and 15.5% of the subjects had significant coronary narrowing.

#### 3.2. Factors associated with FGF-23

FGF-23 levels were significantly correlated with phosphate levels ( $r=0.18$ ,  $p=0.028$ ) and significantly inversely related to eGFR ( $r=-0.201$ ,  $p=0.014$ ) (Table 3). There was no association of FGF23 with 1,25-(OH)<sub>2</sub>-D<sub>3</sub> levels ( $r=-0.132$ ,  $p=0.109$ ). FGF-23 was also significantly negatively correlated with adiponectin levels ( $r=-0.182$ ,  $p=0.043$ ), but not with other lipid parameters or inflammatory markers. There was also no association between serum FGF23 and coronary plaque area (data not shown).

In urine data, FGF-23 was strongly correlated with absolute urine phosphate concentration ( $r=0.564$ ,  $p=0.018$ ). No association was found between FGF-23 and the urine phosphate:creatinine ratio.

### *3.3. Factors associated with coronary calcification*

In univariate regression analysis (Table 4), Agatston scores (reflecting coronary calcification) were significantly associated with age ( $r=0.367$ ,  $p<0.001$ ) and HbA1c ( $r=0.216$ ,  $p=0.008$ ). Among Ca/phosphate metabolism markers, FGF-23 levels showed a weak but significant correlation with Agatston score ( $r=0.169$ ,  $p=0.039$ ) (Figure 2). An inverse relationship was found between eGFR and Agatston scores ( $r=-0.166$ ,  $p=0.043$ ). There was a tendency towards a negative association of Agatston scores with 1,25-(OH)<sub>2</sub>-D<sub>3</sub> levels, but this association failed to reach the level of statistical significance ( $r=-0.156$ ,  $p=0.058$ ). Agatston scores showed no relationship with absolute or adjusted urine phosphate concentrations.

### *3.4. Independent factors associated with coronary calcification*

Based on the results of univariate analysis, age, HbA1c, eGFR, 1,25-(OH)<sub>2</sub>-D<sub>3</sub> and FGF-23 were used in multivariate linear regression analysis of the Agatston score. As shown in Table 5, age, 1,25-(OH)<sub>2</sub>-D<sub>3</sub> and FGF-23 were independently associated with the Agatston score.

## **4. Discussion**

It is well established that the presence of coronary calcification is a good predictor of future cardiac events in patients with and without CKD. However it remains unclear whether mineral metabolism plays a role in the progression of vascular calcification in

patients with preserved renal function. Our study showed that higher serum FGF-23 is associated with coronary calcification independently of age and renal function in patients with suspected coronary artery disease and without kidney disease. FGF-23 regulates circulating phosphate, active vitamin D, and PTH levels, all of which also regulate FGF-23 production from bone. Thus our findings imply that Ca/phosphate metabolism plays a role in promoting coronary calcification, even in patients with preserved renal function. However, the cross sectional design of the study does not permit an assessment of the causality of FGF-23 in progression of coronary calcification in these patients.

Vascular calcification is often observed in older persons and in patients with diabetes or end-stage kidney disease (ESKD). The pathophysiology of vascular calcification in ESKD has been widely investigated. Ca/phosphate metabolic disorder secondary to impaired renal function plays a central role in initiation or progression of vascular calcification. In particular, a high phosphate concentration has a crucial impact on vascular calcification and is an important therapeutic target in CKD patients [26-28]. Recent studies have demonstrated the importance of extracellular phosphate as a substrate for hydroxyapatite formation and as an inducer of gene expression programs that facilitate calcification [29-30]. It is of interest that higher FGF-23, which promotes renal phosphate excretion, is associated with higher mortality in patients with ESKD [12]. Parker et al. also found that higher FGF-23 levels were associated with mortality and composite cardiovascular events in 833 outpatients with coronary artery disease and an eGFR of 70 to 80 mL/min/1.73m<sup>2</sup> [31].

In our study, serum phosphate concentrations were normal in most of the cohort with preserved renal function, as expected, and had no association with vascular calcification. At this level of renal function, the serum phosphate level may be

maintained within a normal range by a compensatory increase of FGF-23, even if the time-averaged phosphate level is high. Our results are consistent with this theory. Thus, FGF-23 may be a surrogate marker for the time-averaged serum phosphate level and might be expected to have a close association with coronary calcification in patients with preserved renal function. We failed to observe an association between urinary phosphate and coronary calcification. However, the number of patients was limited. Examination of a possible association of urinary phosphate excretion with coronary calcification in a larger patient sample should allow a definitive answer to this question.

Another potential explanation of the link between high FGF-23 and an increased risk of vascular disease is the connection of FGF-23 with lipid metabolism. In an evaluation of the relationships between FGF-23 and metabolic cardiovascular risk factors in two independent community-based, cross-sectional cohorts of elderly individuals, Mirza et al. [32] found significant correlations of serum FGF-23 levels with higher BMI, larger waist circumference, elevated triglycerides (TG), and lower HDL-cholesterol (HDL-C). Thus, FGF-23 may exert an indirect effect on lipid metabolism, and as a consequence may promote vascular disease. Indeed, elevated TG [33] and lower HDL-C [34] are closely associated with coronary calcification, and we also found a correlation of FGF-23 with TG, but this did not reach a significant level in our subjects.

A third possible mechanism underlying the link between FGF-23 and vascular disease may involve a connection between adipocytokines and FGF-23. Tsuji et al. recently showed that leptin, a peptide hormone produced by adipocytes and related to total body fat, directly stimulates FGF-23 expression in bone in leptin-deficient mice [35]. FGF-23 levels are also inversely related to those of adiponectin, a hormone that

protects against endothelial damage [36], and elevated leptin and lower adiponectin are well known contributors to vascular calcification in humans [37]. An inverse relationship of FGF-23 with the level of adiponectin was also observed in our study.

A direct effect of FGF-23 on coronary calcification is a final potential explanation for our findings. To our knowledge, there are no studies that support a direct toxic influence of FGF-23 on vascular damage. However, recently, it has been proven that FGF-23 directly affects left ventricular hypertrophy in an animal model [38]. Therefore, it is possible that FGF-23 may have a direct role in progression of vascular damage.

It is of interest that lower  $1,25\text{-(OH)}_2\text{-D}_3$  levels were associated with coronary calcification, independent of age, renal function, and FGF-23. This finding is supported by evidence that not only a high level, but also a low level of  $1,25\text{-(OH)}_2\text{-D}_3$  was associated with significantly greater vascular calcification in pediatric dialysis patients [39]. The potential mechanism may involve the association of low  $1,25\text{-(OH)}_2\text{-D}_3$  levels with higher CRP concentrations, which would promote vascular calcification [40].

There are several limitations in the current study. As mentioned above, based on our study design, elevated FGF-23 can only be defined as a marker of coronary calcification in patients with preserved renal function. Evidence for a causal relationship and clarification of the mechanism of this unique finding will require a longitudinal study of the effect of changes in FGF-23 on vascular calcification. Second, we did not collect urine data, especially for the urine phosphate level, which is mainly regulated by FGF-23. These data may permit development of a hypothesis that phosphate load plays a role in promoting coronary calcification. Third, the number of patients was small and a further investigation in a larger sample size is needed.

## **5. Conclusion**

Serum FGF-23 levels were associated with coronary calcification independently of classical risk factors and also of adipocytokines and inflammatory markers in patients with preserved renal function. A direct effect of FGF-23 on progression of coronary calcification cannot be excluded and a further study is required to examine this issue.

## **Acknowledgement**

We are particularly grateful to Mr. Araki and Mr. Obata, the staff responsible for computed tomography management, for their kind support and assistance.

## **Conflict of Interest**

None of the authors have a conflict of interest regarding the work in the study. Funding was provided from institutional sources only.

## References

1. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *The New England journal of medicine* 358:1336-1345. 2008
2. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with framingham score for risk prediction in asymptomatic individuals. *JAMA* 291:210-215. 2004
3. Raggi P, Callister TQ, Coil B, He ZX, Lippolis NJ, Russo DJ, Zelinger A, Mahmarian JJ. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 101:850-855. 2000
4. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. *Radiology* 228:826-833. 2003
5. Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Cury RC, Abbara S, Brady TJ, Budoff MJ, Blumenthal RS, Nasir K. Diagnostic and prognostic value of absence of coronary artery calcification. *JACC Cardiovasc Imag* 2009;2:675-88.
6. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N. Vascular calcification in chronic kidney disease. *Am J Kidney Dis* 2004;43:572-9.
7. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. Fgf-23 is a potent regulator of vitamin d metabolism and phosphate homeostasis. *J Bone Miner Res* 19:429-435. 2004
8. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of fgf23 demonstrates an essential physiological role of fgf23 in phosphate and vitamin d metabolism. *The Journal of clinical investigation* 113:561-568. 2004
9. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin d. *J Am Soc Nephrol* 17:1305-1315. 2006
10. Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HAt, Hsieh JC, Slater SA, Hsieh G, Kaczmarek M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR. 1,25-dihydroxyvitamin d3/vdr-mediated induction of fgf23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. *J Steroid Biochem Mol Biol* 103:381-388. 2007



11. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. *Am J Kidney Dis* 2004;44:250-6.
12. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med* 2008; 359:584-92.
13. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. *Hemodial Int* 2010;14:425-32.
14. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Druke TB, Massy ZA; on behalf of the European Uremic Toxin (EUTox) Work Group. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. *Osteoporos Int*. 2012 Jul;23(7):2017-2025. Epub 2011 Nov 23.
15. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. *Nephrol Dial Transplant* (2010) 25: 2679–2685
16. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. High levels of serum fibroblast growth factor (fgf)-23 are associated with increased mortality in long haemodialysis patients. *Nephrol Dial Transplant* 24:2792-2796. 2009
17. Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. *Clin J Am Soc Nephrol* 2010;5:1780-6.
18. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney Int* 2011;79:1370-8.
19. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated gfr from serum creatinine in japan. *Am J Kidney Dis* 2009;53:982-92.
20. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Increased circulatory level of

- biologically active full-length fgf-23 in patients with hypophosphatemic rickets/osteomalacia. *J Clin Endocrinol Metab* 2002;87:4957-60.
21. Sato Y, Matsumoto N, Kato M, Inoue F, Horie T, Kusama J, Yoshimura A, Imazeki T, Fukui T, Furuhashi S, Takahashi M, Kanmatsuse K. Noninvasive assessment of coronary artery disease by multislice spiral computed tomography using a new retrospectively ecg-gated image reconstruction technique. *Circ J* 2003;67:401-5.
  22. Sato Y, Kanmatsuse K, Inoue F, Horie T, Kato M, Kusama J, Yoshimura A, Imazeki T, Furuhashi S, Takahashi M. Noninvasive coronary artery imaging by multislice spiral computed tomography. *Circ J* 2003;67:107-11.
  23. Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, Ohnesorge B, Fayad ZA, Becker CR, Reiser M, Steinbeck G, Boekstegers P. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: A comparative study using intravascular ultrasound. *J Am Coll Cardiol* 2006;47:672-7.
  24. Leber AW, Knez A, Becker A, Becker C, von Ziegler F, Nikolaou K, Rist C, Reiser M, White C, Steinbeck G, Boekstegers P. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: A comparative study with intracoronary ultrasound. *J Am Coll Cardiol* 2004;43:1241-7.
  25. Takaiwa M, Aya K, Miyai T, Hasegawa K, Yokoyama M, Kondo Y, Kodani N, Seino Y, Tanaka H, Morishima T. Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period. *Bone* 2010;47:256-62.
  26. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int Suppl* 2009:S1-130.
  27. K/DOQI clinical practice guidelines for bone metabolism and disease in disease. *Am J Kidney Dis* 2003;42:S1-201.
  28. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. *Ther Apher Dial* 2008;12:514-25.
  29. Giachelli CM. The emerging role of phosphate in vascular calcification. *Kidney Int* 2009;75:890-7.
  30. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res* 2000;87:E10-7.
  31. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor

- 23 and uncarboxylated matrix gla protein with mortality in coronary artery disease: The heart and soul study. *Ann Intern Med* 2010;152:640-8.
32. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. *Arterioscler, Thromb Vasc Biol* 2011;31:219-27.
  33. Martin SS, Qasim AN, Wolfe M, St Clair C, Schwartz S, Iqbal N, Schutta M, Bagheri R, Mehta NN, Rader DJ, Reilly MP. Comparison of high-density lipoprotein cholesterol to apolipoprotein a-i and a-ii to predict coronary calcium and the effect of insulin resistance. *Am J Cardiol* 2011;107:393-8.
  34. Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. *Atherosclerosis* 2009;202:289-95.
  35. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin d3 synthesis in leptin-deficient mice. *J Bone Miner Res* 2010;25:1711-23.
  36. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. *FEBS Lett* 2008;582:74-80.
  37. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. *J Clin Endocrinol Metab* 2004;89:3872-8.
  38. Faul C, Amaral AP, Oskoueï B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguilon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. *J Clin Invest* 2011;121:4393-408
  39. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L. A bimodal association of vitamin D levels and vascular disease in children on dialysis. *J Am Soc Nephrol* 19: 1239–1246, 2008
  40. Drüeke TB, Massy ZA. Role of vitamin D in vascular calcification: bad guy or good guy? *Nephrol Dial Transplant* (2012) 27: 1704–1707

## Figure legends

### Figure 1

Histograms of absolute and Log transformed FGF-23 levels. Absolute FGF-23 had a near normal distribution.

### Figure 2

A weak but significant correlation of serum FGF23 level with Agatston score was observed ( $r=0.169$ ,  $p=0.039$ ) by Pearson univariate regression analysis.

Table 1: Characteristics of patients with eGFR >60 ml/min/1.73m<sup>2</sup> without proteinuria #

Age, years	65.5 (55, 72)
Male, %	81(54.7)
Body mass index, kg/m <sup>2</sup>	23.1 (21.2, 25.5)
Smoker, %	73(49.3)
Systolic blood pressure, mmHg	130 (120, 140)
Diastolic blood pressure, mmHg	78 (70, 82)
Hypertension, %	83(56.1)
Dyslipidemia, %	87(58.7)
Angina pectoris, %	5(3.3)
Myocardial infarction, %	3(2)
Statin, %	42(28.3)
β-blocker, %	9(6)
RAS, %	38(25.6)
CCB, %	51(34.4)
Diuretics, %	8(5.4)
Antiplatelet, %	27(18.2)
LDL-C, mg/dl	114 (92, 131)
HDL-C, mg/dl	54 (43, 64)
Triglyceride, mg/dl	117 (79, 182)
HbA1c, %	5.2 (5, 5.5)
IRI, μU/ml	4.3 (3, 8.3)
HOMA index	1.04 (0.88, 1.91)

Serum creatinine, mg/dl	0.7 (0.62, 0.83)
eGFR, ml/min/1.73m <sup>2</sup>	74.6 (66.7, 83.5)
C-reactive protein, mg/dl	0.046 (0.029, 0.298)
Calcium, mg/dl	9.5 (9.3, 9.8)
Phosphorus, mg/dl	3.7 (3.3, 4.1)
Calcium-phosphorus product	35.5 (31.6, 38.8)
Serum FGF-23, pg/ml	26 (21, 33)
Log Serum FGF-23	1.41(1.32, 1.51)
Whole PTH, pg/ml	36.6 (29.3, 47.4)
1,25-(OH) <sub>2</sub> -D <sub>3</sub> , pg/ml	56 (45, 76)
Leptin, ng/ml	7.1 (4.4, 9.9)
TNF- $\alpha$ , pg/ml	0.99 (0.79, 1.29)
Adiponectin, $\mu$ g/ml	7.6 (5.6, 10.7)
Agatston score	11.5 (0, 193)
Urine creatinine, mg/dL*	119.4(70.8, 140.2)
Urine phosphate, mg/dL*	43.9(28.6, 58)
Urine phosphate, mg/dl (corrected for creatinine)*	0.44(0.29, 0.52)

Data are presented as n (%) or median (interquartile range).

# The range of eGFR was 60-112 mL/min/1.73<sup>2</sup>

\* Analysis performed in 17 patients

Table 2: Coronary characteristics

	mean	median
Agatston score	149±276	11.5
Calcified plaques (%)	54.7	
Non-calcified plaques (%)	23.6	
Significant stenosis (%)	15.5	

Table 3:

Univariate linear regression analysis for factors associated with serum FGF-23

Variables	r	95%CI	P value
BMI	0.038	-0.397 - 0.641	0.642
Triglyceride	0.112	0.005 - 0.026	0.173
LDL	0.025	-0.045 - 0.061	0.760
HDL	-0.073	-0.184 - 0.07	0.38
L/H	0.075	-1.067 - 2.867	0.367
Leptin	0.132	-0.055 - 0.474	0.119
Adiponectin	-0.182	-0.729 - -0.011	0.043
TNF- $\alpha$	-0.043	-1.297 - 0.899	0.719
C-reactive protein	-0.032	-18.708 - 13.165	0.731
eGFR	-0.201	-0.33 - -0.037	0.014
Calcium	0.037	-3.414 - 5.417	0.654
Phosphorus	0.18	0.285 - 5.165	0.028
1,25-(OH) $_2$ -D $_3$	-0.132	-0.142 - 0.015	0.109
whole PTH	0.033	-0.077 - 0.116	0.691
Spot urine phosphate, mg/dl*	0.564	0.037 - 0.348	0.018
Spot urine phosphate, mg/dl correct creatinine*	0.011	-41.06 - 42.758	0.966

\* Analysis performed in 17 patients



Table 4:

Univariate linear regression analysis for factors associated with Agatston score

Variables	r	95%CI	P value
Age	0.367	4.787 - 11.564	<0.001
HbA1c	0.216	46.246 - 306.901	0.008
LDL-C	0.008	-1.319 - 1.458	0.921
HDL-C	-0.087	- 5.088 - 1.552	0.294
Triglyceride	-0.025	-0.466 - 0.343	0.764
SBP	0.065	- 1.827 - 4.275	0.429
DBP	-0.047	- 6.044 - 3.339	0.569
eGFR	-0.166	- 7.831 - -0.115	0.043
Creatinine	0.056	-215.125 - 442.188	0.495
BMI	0.05	-9.371 - 17.748	0.542
C-reactive protein	0.076	-234.134 - 558.593	0.419
TNF- $\alpha$	0.071	- 23.337 - 42.845	0.558
HOMA index	0.037	- 5.058 - 8.015	0.655
Adiponectin	0.004	- 9.565 - 9.99	0.965
Leptin	0.055	- 4.477 - 8.908	0.513
Calcium	-0.129	-205.787 - 23.24	0.117
Phosphorus	0.067	- 31.755 - 76.126	0.417
Whole PTH	0.134	- 0.434 - 4.556	0.104
Ca $\times$ P	0.04	- 4.005 - 6.637	0.625
1,25-(OH) $_2$ -D3	-0.156	- 4.006 - 0.69	0.058
Serum FGF-23	0.169	0.216 - 8.642	0.039

Log FGF-23	0.163	1.575 - 525.178	0.048
Spot urine phosphate, mg/dl*	-0.27	-6.183 - 2.012	0.295
Spot urine phosphate, mg/dl correct creatinine*	-0.27	-1380 - 447	0.294

\* Analysis performed in 17 patients

Table 5: Multiple linear regression analysis for factors associated with Agatston score

Variables	$\beta$	95%CI	P value
Age	0.376	4.82 - 11.948	<0.001
Serum FGF-23	0.188	0.922 - 8.913	0.016
eGFR	0.008	-3.589 - 3.970	0.92
1,25-(OH)2-D3	-0.175	-4.080 - -0.334	0.021
HbA1c	0.129	-18.051 - 228.987	0.093
R <sup>2</sup>	0.224		<0.001

**Figure 1**




Figure 2

